Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03416907
Other study ID # STUDY2017_00000268
Secondary ID
Status Completed
Phase N/A
First received January 8, 2018
Last updated January 24, 2018
Start date November 27, 2017
Est. completion date December 31, 2017

Study information

Verified date January 2018
Source Carnegie Mellon University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study will test whether different formats of medical informed consent documents can help improve understanding and confidence in decision-making for clinical trials. The study will be primarily run through an online survey.


Description:

The goal of this study is to investigate whether the same information can be communicated in different formats of an informed consent document in ways that improve participant understanding and confidence. Participants will review one of several different versions of the same informed consent document, and will be asked to complete a survey after reading the documents. The survey will ask participants their willingness to enroll in the clinical trial discussed in the document and their confidence in their decision. The survey will also test participants recollection of information from the informed consent document. Researchers will look at this data to see if there are ways to improve knowledge about the clinical trial and confidence in decisions without necessarily changing enrollment preferences.


Recruitment information / eligibility

Status Completed
Enrollment 500
Est. completion date December 31, 2017
Est. primary completion date December 31, 2017
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- 18 Years Old or Older

- Read and agreed to informed consent

- Indicated desire to participate

- Diagnosed with asthma

- US resident

Exclusion Criteria:

- Participants from whom we receive multiple responses will be dropped from analysis (but will be compensated for participation)

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
Original consent form
Participants will review the full-length, original consent form for the clinical trial.
Shortened consent form
Participants will review a shortened consent form for the clinical trial, which includes only material indicated as important by 2/3 of participants from a previous study.
Reordered, shortened consent form
Participants will review a reordered, shortened consent form. This form is based on the shortened consent form, but the sections are reordered based on a previous study, such that sentences previously rated as more likely to impact a participant's decision is more likely to be presented first (except for an initial introductory section).
Shortened consent form with a highlights box
Participants will review a shortened consent form with a highlights box, where the highlights box includes the 10 sentences rates as most likely to impact a participant's decision from a previous study.
Interactive, shortened consent form
Participants will review an interactive, shortened consent form, where hyperlinks to different sections of the consent form are provided. The landing page includes the introductory section.

Locations

Country Name City State
United States Carnegie Mellon University Pittsburgh Pennsylvania

Sponsors (2)

Lead Sponsor Collaborator
Carnegie Mellon University ICON plc

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Other Participant's free-response text describing what was learned from reading the informed consent document Survey question of the following form:
"What are some of the key things you learned from reading the informed consent document?"
Participants are then provided with an free-response text box where they are allowed to enter whatever text they want, as long as they enter some text. These responses will be coded by two independent coders, blinded to the treatment arms, using an emergent coding system to identify different topics that participants may raise.
through study completion, an average of 30 minutes
Primary Score for high impact questions Sum of correct answers (T/F) for any item relating to material that was rated as 50 or higher on impact on willingness to enroll in a previous study. through study completion, an average of 30 minutes
Secondary Score for low impact questions Sum of correct answers (T/F) for any item relating to material that was rated as 49 or lower on impact on willingness to enroll in a previous study. through study completion, an average of 30 minutes
Secondary Total score for all questions Sum of correct answers (T/F) on full knowledge test. through study completion, an average of 30 minutes
Secondary Interaction effect of format and importance on likelihood of correct answer Interaction effect in a logistic regression predicting a correct answer, based on the format of the consent form and the importance of the answer. through study completion, an average of 30 minutes
Secondary Scores for different information categories Sum of correct answers (T/F) for each of the 20 information categories through study completion, an average of 30 minutes
Secondary Effect of location on score Logistic regression coefficient of likelihood of predicting a correct answer, based upon the location on which the sentence appeared--uses only the shortened, and the reordered conditions. Note that sentences appearing in the introduction (which is the first section of all treatments) must be dropped, as there will be no variation in location. through study completion, an average of 30 minutes
Secondary Decision to enroll Likert measure of participants hypothetical decision to enroll in the study through study completion, an average of 30 minutes
Secondary Confidence in enrollment decision Likert measure of participants confidence in hypothetical decision to enroll in the study through study completion, an average of 30 minutes
Secondary Satisfaction with consent structure Likert measure of participants satisfaction with the consent form through study completion, an average of 30 minutes
Secondary Perception of investigator concern for well being Likert measure of participants belief in the investigator's concerns for the participant's well-being through study completion, an average of 30 minutes
Secondary Perception of investigator transparency Likert measure of participants belief that the investigator is trying to communicate information about the trial accurately through study completion, an average of 30 minutes
Secondary Participant's probability estimate of the likelihood that the treatment would help control their asthma Survey question of the following form:
'If you enrolled in the trial described in the consent form, what is the probability that the treatment could help control your asthma better, where 0% means "no chance at all of helping" and 100% means "would definitely help"?'
Participants provided with drop-down menu including values from 0% to 100% in increments of 1%.
through study completion, an average of 30 minutes
See also
  Status Clinical Trial Phase
Completed NCT04624425 - Additional Effects of Segmental Breathing In Asthma N/A
Terminated NCT04410523 - Study of Efficacy and Safety of CSJ117 in Patients With Severe Uncontrolled Asthma Phase 2
Active, not recruiting NCT03927820 - A Pharmacist-Led Intervention to Increase Inhaler Access and Reduce Hospital Readmissions (PILLAR) N/A
Completed NCT04617015 - Defining and Treating Depression-related Asthma Early Phase 1
Recruiting NCT03694158 - Investigating Dupilumab's Effect in Asthma by Genotype Phase 4
Terminated NCT04946318 - Study of Safety of CSJ117 in Participants With Moderate to Severe Uncontrolled Asthma Phase 2
Completed NCT04450108 - Vivatmo Pro™ for Fractional Exhaled Nitric Oxide (FeNO) Monitoring in U.S. Asthmatic Patients N/A
Completed NCT03086460 - A Dose Ranging Study With CHF 1531 in Subjects With Asthma (FLASH) Phase 2
Completed NCT01160224 - Oral GW766944 (Oral CCR3 Antagonist) Phase 2
Completed NCT03186209 - Efficacy and Safety Study of Benralizumab in Patients With Uncontrolled Asthma on Medium to High Dose Inhaled Corticosteroid Plus LABA (MIRACLE) Phase 3
Completed NCT02502734 - Effect of Inhaled Fluticasone Furoate on Short-term Growth in Paediatric Subjects With Asthma Phase 3
Completed NCT01715844 - L-Citrulline Supplementation Pilot Study for Overweight Late Onset Asthmatics Phase 1
Terminated NCT04993443 - First-In-Human Study to Evaluate the Safety, Tolerability, Immunogenicity, and Pharmacokinetics of LQ036 Phase 1
Completed NCT02787863 - Clinical and Immunological Efficiency of Bacterial Vaccines at Adult Patients With Bronchopulmonary Pathology Phase 4
Recruiting NCT06033833 - Long-term Safety and Efficacy Evaluation of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-severe Asthma Who Completed Treatment Period of Previous Amlitelimab Asthma Clinical Study Phase 2
Completed NCT03257995 - Pharmacodynamics, Safety, Tolerability, and Pharmacokinetics of Two Orally Inhaled Indacaterol Salts in Adult Subjects With Asthma. Phase 2
Completed NCT02212483 - Clinical Effectiveness and Economical Impact of Medical Indoor Environment Counselors Visiting Homes of Asthma Patients N/A
Recruiting NCT04872309 - MUlti-nuclear MR Imaging Investigation of Respiratory Disease-associated CHanges in Lung Physiology
Withdrawn NCT01468805 - Childhood Asthma Reduction Study N/A
Recruiting NCT05145894 - Differentiation of Asthma/COPD Exacerbation and Stable State Using Automated Lung Sound Analysis With LungPass Device